Clin Nutr Res.  2017 Apr;6(2):130-135. 10.7762/cnr.2017.6.2.130.

Nicotinamide Reduces Amyloid Precursor Protein and Presenilin 1 in Brain Tissues of Amyloid Beta-Tail Vein Injected Mice

• Kim EJ
• Yang SJ

• KMID: 2383701
• DOI: http://doi.org/10.7762/cnr.2017.6.2.130

Abstract

The purpose of this study is to investigate whether nicotinic acid (NA) and nicotinamide (NAM) reduce the Alzheimer disease (AD)-related gene expression in brain tissues of amyloid beta (Aβ)-injected mice. Male Crj:CD1 (ICR) mice were divided into 6 treatment groups; 1) control, 2) Aβ control, 3) Aβ + NA 20 mg/kg/day (NA20), 4) Aβ + NA40, 5) Aβ + NAM 200 mg/kg/day (NAM200), and 6) Aβ + NAM400. After 1-week acclimation period, the mice orally received NA or NAM once a day for a total of 7 successive days. On day 7, biotinylated Aβ42 was injected into mouse tail vein. At 5 hours after the injection, blood and tissues were collected. Aβ42 injection was confirmed by Western blot analysis of Aβ42 protein in brain tissue. NAM400 pre-treatment significantly reduced the gene expression of amyloid precursor protein and presenilin 1 in brain tissues. And, NAM200 and NAM400 pre-treatments significantly increased sirtuin 1 expression in brain tissues, which is accompanied by the decreased brain expression of nuclear factor kappa B by 2 doses of NAM. Increased expression of AD-related genes was attenuated by the NAM treatment, which suggests that NAM supplementation may be a potential preventive strategy against AD-related deleterious changes.

Keyword

Aging; Alzheimer disease; β-amyloid; Niacin

MeSH Terms

Acclimatization
Aging
Alzheimer Disease
Amyloid*
Animals
Blotting, Western
Brain*
Gene Expression
Humans
Male
Mice*
NF-kappa B
Niacin
Niacinamide*
Presenilin-1*
Presenilins*
Sirtuin 1
Tail
Veins*
Amyloid
NF-kappa B
Niacin
Niacinamide
Presenilin-1
Presenilins
Sirtuin 1

Figure

• 

  Figure 1 Aβ tail vein injection increases brain Aβ levels. Brain tissues were collected and analyzed via western blot using anti-Aβ antibody. Aβ levels were quantified and data are expressed as mean ± SEM. Aβ, amyloid beta; SEM, standard error of the mean; CON, control. *p < 0.05 compared with CON.

• 

  Figure 2 NAM reduces 2 AD-related targets (A) APP and (B) PS1, and inflammation-related targets (C) Sirt1 and NF-κB in brain tissues of Aβ tail vein-injected mice. Data are expressed as mean ± SEM. Different letters within a variable are significantly different at p < 0.05. NAM, nicotinamide; AD, Alzheimer disease; APP, amyloid precursor protein; PS1, presenilin 1; Sirt1, sirtuin 1; NF-κB, nuclear factor kappa B; SEM, standard error of the mean; CON, control; NA, nicotinic acid.

Reference

1. Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer's disease. Lancet. 2016; 388:505–517.

2. Czeczor JK, McGee SL. Emerging roles for the amyloid precursor protein and derived peptides in the regulation of cellular and systemic metabolism. J Neuroendocrinol. Forthcoming. 2017.

3. Zoltowska KM, Berezovska O. Dynamic nature of presenilin1/γ-secretase: implication for Alzheimer's disease pathogenesis. Mol Neurobiol. Forthcoming. 2017.

4. Reddy PH. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp Neurol. 2009; 218:286–292.

5. França MB, Lima KC, Eleutherio EC. Oxidative stress and amyloid toxicity: insights from yeast. J Cell Biochem. 2017; 118:1442–1452.

6. Bolós M, Perea JR, Avila J. Alzheimer's disease as an inflammatory disease. Biomol Concepts. 2017; 8:37–43.

7. Turunc Bayrakdar E, Uyanikgil Y, Kanit L, Koylu E, Yalcin A. Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in Aβ(1-42)-induced rat model of Alzheimer's disease. Free Radic Res. 2014; 48:146–158.

8. Gong B, Pan Y, Vempati P, Zhao W, Knable L, Ho L, Wang J, Sastre M, Ono K, Sauve AA, Pasinetti GM. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol Aging. 2013; 34:1581–1588.

9. Chi Y, Sauve AA. Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection. Curr Opin Clin Nutr Metab Care. 2013; 16:657–661.

10. McIntee FL, Giannoni P, Blais S, Sommer G, Neubert TA, Rostagno A, Ghiso J. In vivo differential brain clearance and catabolism of monomeric and oligomeric Alzheimer's Aβ protein. Front Aging Neurosci. 2016; 8:223.

11. Wang Y, Zuo M. Nicotinamide improves sevoflurane-induced cognitive impairment through suppression of inflammation and anti-apoptosis in rat. Int J Clin Exp Med. 2015; 8:20079–20085.

12. Lee HJ, Hong YS, Jun W, Yang SJ. Nicotinamide riboside ameliorates hepatic metaflammation by modulating NLRP3 inflammasome in a rodent model of type 2 diabetes. J Med Food. 2015; 18:1207–1213.

13. Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD⁺ precursor vitamins in human nutrition. Annu Rev Nutr. 2008; 28:115–130.

14. Liu Z, Gan L, Liu G, Chen Y, Wu T, Feng F, Sun C. Sirt1 decreased adipose inflammation by interacting with Akt2 and inhibiting mTOR/S6K1 pathway in mice. J Lipid Res. 2016; 57:1373–1381.

15. Ye X, Li M, Hou T, Gao T, Zhu WG, Yang Y. Sirtuins in glucose and lipid metabolism. Oncotarget. 2017; 8:1845–1859.